Sugi Predict

Sugi Predict / Compounds / SCHEMBL1853822

SCHEMBL1853822

SCHEMBL1853822

CC(C)(C)OC(=O)N1C[C@@H](F)C[C@@H]1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.42
▸ NR1H2 P55055 1/20 0.39
▸ CHRM2 P08172 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ CHRM3 P20309 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ HSD11B1 P28845 1/20 0.37
▸ HTRA1 Q92743 1/20 0.36
▸ BTK Q06187 1/20 0.35
▸ DPP4 P27487 2/20 0.34
▸ UCHL1 P09936 1/20 0.34
▸ USP30 Q70CQ3 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ PEPD P12955 1/20 0.33
▸ XPNPEP1 Q9NQW7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20811620 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL38017 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL17760125 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL192501 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL2489604 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL192921 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL641763 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL29038999 1.00 HSD17B10 (0.42) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL1334717 0.87 NR1H2 (0.39) HSD17B10NR1H2CHRM2CHRM1CHRM3
SCHEMBL15116701 0.87 NR1H2 (0.39) HSD17B10NR1H2CHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4695236-A1 SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE Soley Therapeutics, Inc. (US) 2026-02-18 — — EP disclosed
EP-4676929-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 Dark Blue Therapeutics Ltd (GB) 2026-01-14 — — EP disclosed
US-20250368641-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORP (US) 2025-12-04 — — US disclosed
EP-4638447-A1 IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS Dark Blue Therapeutics Ltd (GB) 2025-10-29 — — EP disclosed
US-12378243-B2 Quinoline compounds as inhibitors of KRAS INCYTE CORPORATION (US) 2025-08-05 — — US disclosed
US-20250049780-A1 THIENOPYRROLE COMPOUNDS GILEAD SCIENCES, INC. 2025-02-13 — — US disclosed
US-12161625-B2 Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (US) 2024-12-10 — — US disclosed
US-20240368152-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORPORATION 2024-11-07 — — US disclosed
WO-2024216094-A1 SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE SOLEY THERAPEUTICS, INC. (US) 2024-10-17 — — WO disclosed
US-20240327402-A1 PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY ABBISKO THERAPEUTICS CO., LTD. (CN) 2024-10-03 — — US disclosed
EP-3019475-A1 ARYL AMIDE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2016-05-18 — — EP disclosed
WO-2015006100-A1 ARYL AMIDE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2015-01-15 — — WO disclosed
US-20140221332-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2014-08-07 — — US disclosed
US-20140221332-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2014-08-07 — — US disclosed
US-8796470-B2 Substituted octahydrocyclopenta[c]pyrroles as calcium channel modulators ABBVIE INC. (US) 2014-08-05 — — US disclosed
WO-2012162635-A1 METABOTROPIC GLUTAMATE RECEPTORS 5 MODULATORS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2012-11-29 — — WO disclosed
US-20110294854-A1 SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2011-12-01 — — US disclosed
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 — — EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 — — US disclosed
WO-2004032834-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2004-04-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250049780-A1 THIENOPYRROLE COMPOUNDS SSB, TPMT, LCP2 HSD17B10 3762/4885NR1H2 1364/4885CHRM2 3105/4885
US-12161625-B2 Substituted pyrrolizine compounds and uses thereof HMBS, DHFR, HCCS HSD17B10 2331/4885NR1H2 1180/4885CHRM2 4848/4885
US-12378243-B2 Quinoline compounds as inhibitors of KRAS KRAS, NRAS, HRAS HSD17B10 3790/4885NR1H2 882/4885CHRM2 4782/4885
US-20240368152-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS KRAS, NRAS, HRAS HSD17B10 3790/4885NR1H2 882/4885CHRM2 4782/4885
US-20140221332-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF GRM5, GRIK5, GRM2 HSD17B10 1045/4885NR1H2 371/4885CHRM2 591/4885
US-20240327402-A1 PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY WEE1, WEE2, EGFR HSD17B10 2635/4885NR1H2 2341/4885CHRM2 4854/4885
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 HSD17B10 1290/4885NR1H2 3135/4885CHRM2 334/4885
US-20250368641-A1 QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS KRAS, NRAS, HRAS HSD17B10 3790/4885NR1H2 882/4885CHRM2 4782/4885
US-20110294854-A1 SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS ORAI1, CACNA1E, RYR1 HSD17B10 2754/4885NR1H2 1912/4885CHRM2 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.